Gabriel S. Morris
CFO at Immix Biopharma Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Immix Biopharma Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Immix Biopharma Inc. May 22, 202695.8%
-
Immix Biopharma Inc. June 20, 202598.3%
-
Immix Biopharma Inc. June 11, 202496.5%
-
Immix Biopharma Inc. June 7, 202397.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 10, 2025 | Immix Biopharma Inc. | Open-market purchase | +770 | $6.58 | $5,067 |
| Dec 8, 2025 | Immix Biopharma Inc. | In-the-money exercise | +156,000 | $0.80 | $124,800 |
| Sep 16, 2025 | Immix Biopharma Inc. | Open-market purchase | +2,600 | $1.97 | $5,122 |
| Jun 18, 2025 | Immix Biopharma Inc. | Open-market purchase | +2,225 | $2.28 | $5,073 |
| Jun 7, 2024 | Immix Biopharma Inc. | Open-market purchase | +2,500 | $2.12 | $5,300 |
| Jun 4, 2024 | Immix Biopharma Inc. | Open-market purchase | +3,300 | $1.81 | $5,973 |
| May 20, 2024 | Immix Biopharma Inc. | Grant or award | +194,218 | — | — |
| May 20, 2024 | Immix Biopharma Inc. | Grant or award | +24,141 | — | — |
| May 20, 2024 | Immix Biopharma Inc. | Grant or award | +24,141 | — | — |
| May 14, 2024 | Immix Biopharma Inc. | Open-market purchase | +4,500 | $2.23 | $10,035 |
Questions about Gabriel S. Morris
What boards is Gabriel S. Morris on?
Gabriel S. Morris sits on the board of Immix Biopharma Inc.
How long has Gabriel S. Morris served on boards?
Our records show at least 3 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.